Array CGH As a Complementary Tool in the Diagnosis of Myelodysplastic Syndromes

@inproceedings{Abaigar2012ArrayCA,
  title={Array CGH As a Complementary Tool in the Diagnosis of Myelodysplastic Syndromes},
  author={Maria Abaigar and Eva Lumbreras and Irene Rodr{\'i}guez and Javier S{\'a}nchez-del-Real and Mar{\'i}a D{\'i}ez-Campelo and Rebeca Cuello and Jos{\'e} Manuel Mart{\'i}n Alonso and Isabel Recio and Javier Garc{\'i}a Frade and Lourdes Hermos{\'i}n and Juan Antonio Noriega Rodr{\'i}guez and Marta Megido and Magdalena Sierra and Guillermo Mart{\'i}n-N{\'u}{\~n}ez and Tom{\'a}s Gonz{\'a}lez and Manuel Vargas and Jos{\'e} Luis Fuster and Pilar Giraldo and Jes{\'u}s Ma Hern{\'a}ndez and Jesús F. San Miguel},
  year={2012}
}
Abstract 3827 Background: Myelodysplastic syndromes (MDS) are a heterogeneous group of hematological disorders in which diagnosis, risk stratification, and treatment selection are based on morphological and cytogenetic studies in bone marrow (BM) samples. MDS are characterized by several recurrent chromosomal abnormalities, most of them unbalanced, with a widely variable prognosis. The assessment of these genomic defects is essential for a correct risk stratification of these patients. However… CONTINUE READING

Topics from this paper.